文献速递药疹与重症皮肤不良反应皮肤肿瘤

恩科拉非尼与比美替尼治疗B-快速加速纤维肉瘤突变晚期黑色素瘤期间皮肤不良事件的谱系

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-12-13

在苏黎世大学医院临床试验中,接受恩科拉非尼单药(n=24)、比美替尼单药(n=25)及两药联合(n=49)的BRAF突变晚期黑色素瘤患者中,恩科拉非尼单药最常见皮肤不良事件为掌跖角化过度(54%)、掌跖红斑感觉异常(58%)和脱发(46%),比美替尼单药以药物性丘疹脓疱性皮疹为主,联合治疗最常见为掌跖角化过度(10%)。作者认为,与已上市的BRAF抑制剂数据相比,恩科拉非尼单药增生性皮肤不良事件较少,但掌跖角化过度和掌跖红斑感觉异常似乎更常见;联合治疗耐受良好且诱发皮肤不良事件少。

要点

  • 恩科拉非尼单药常见掌跖角化过度(54%)、掌跖红斑感觉异常(58%)和脱发(46%)。
  • 比美替尼单药以药物性丘疹脓疱性皮疹为主。
  • 恩科拉非尼联合比美替尼耐受良好,皮肤不良事件少。

核心结论

  • 与已上市的BRAF抑制剂已发表数据相比,恩科拉非尼单药增生性皮肤不良事件较少,但掌跖角化过度和掌跖红斑感觉异常似乎更常见。
  • 恩科拉非尼与比美替尼联合耐受良好且诱发皮肤不良事件少。

研究设计与样本

  • 在苏黎世大学医院临床试验中识别接受BRAF和MEK抑制剂治疗的患者,基于前瞻性收集的临床和组织病理学数据评估皮肤不良事件的发生频率、特征及管理,并与该机构其他BRAF和MEK抑制剂及文献数据比较。
  • 恩科拉非尼单药组n=24,比美替尼单药组n=25,恩科拉非尼/比美替尼联合组n=49。

主要发现

  • 恩科拉非尼单药组最常见皮肤不良事件为掌跖角化过度(54%)、掌跖红斑感觉异常(58%)和脱发(46%)。
  • 比美替尼单药组以药物性丘疹脓疱性皮疹为主。
  • 恩科拉非尼/比美替尼联合组最常见皮肤不良事件为掌跖角化过度(10%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: B-rapidly accelerated fibrosarcoma (BRAF) inhibitor encorafenib alone and in combination with MEK inhibitor binimetinib improves survival in BRAF-mutated melanoma patients. So far, the range of cutaneous adverse events has been characterized only for established BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib, cobimetinib). OBJECTIVE: The aim of this study was to investigate cutaneous adverse events emerging in melanoma patients treated with encorafenib and binimetinib. METHODS: Patients treated with BRAF and MEK inhibitors in clinical trials at the University Hospital of Zurich were identified. Frequency and features of cutaneous adverse events as well as their management were assessed based on the prospectively collected clinical and histopathological data. The events emerging during encorafenib and/or binimetinib therapy were compared to other BRAF and MEK inhibitors at the institution and in the literature. RESULTS: The most frequent cutaneous adverse events observed in patients treated with encorafenib alone (n = 24) were palmoplantar hyperkeratosis (54%), palmoplantar erythrodysesthesia (58%) and alopecia (46%). Drug-induced papulopustular eruptions prevailed in patients with binimetinib monotherapy (n = 25). The most frequent cutaneous adverse events in patients treated with encorafenib/binimetinib (n = 49) were palmoplantar hyperkeratosis (10%). CONCLUSION: Compared to data published for established BRAFi, encorafenib monotherapy showed less hyperproliferative cutaneous adverse events. In contrast, palmoplantar hyperkeratosis and palmoplantar erythrodysesthesia seem to occur more often. The combination of encorafenib and binimetinib is well tolerated and induces few cutaneous adverse events.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Graf NP, Koelblinger P, Galliker N, et al. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. J Eur Acad Dermatol Venereol. 2018. PMID: 30468696. doi:10.1111/jdv.15363

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。